Skip to main content
Erschienen in: Social Psychiatry and Psychiatric Epidemiology 7/2018

23.04.2018 | Original Paper

Attempting to stop antipsychotic medication: success, supports, and efforts to cope

verfasst von: Miriam Larsen-Barr, Fred Seymour, John Read, Kerry Gibson

Erschienen in: Social Psychiatry and Psychiatric Epidemiology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore supports and coping strategies used during attempts to discontinue antipsychotic medication and test for associations with success.

Method

144 people who were taking or had taken antipsychotics completed The Experiences of Antipsychotic Medication Survey. Among them, 105 people had made at least one discontinuation attempt and answered a series of questions about their most recent attempt to stop. Content analysis and Chi-square tests of independence were used to categorise the data and explore associations. Success was defined as stopping all AM use irrespective of the duration of the medication-free period or whether relapse occurred, which were explored separately.

Results

Among the 105 people who had attempted discontinuation, 61.9% described unwanted withdrawal effects and 27.6% of the group described psychotic or manic relapse during the withdrawal period. Within this group 55% described successfully stopping all AM for varying lengths of time, half reported no current use, and half described having some form of professional, family, friend, and/or service user or peer support for their attempt. Having support was positively associated with success and negatively associated with both current use, and relapse during withdrawal. A range of coping efforts were described, but having coping strategies failed to show significant associations with any of the dependent variables explored. Among those who described successfully stopping, some described returning to AM for short periods when needed, while others reported managing well with alternative methods alone.

Conclusions

Findings cannot be readily generalised due to sampling constraints, but results suggest a wide range of supports and coping strategies may be used when attempting to discontinue antipsychotics. Many people may attempt to discontinue antipsychotics without any support. Those who have support for their attempts may be significantly less likely to relapse during withdrawal and more likely to succeed in their attempt. There is a pressing need for further research in this area.
Literatur
1.
Zurück zum Zitat Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223CrossRefPubMed
2.
Zurück zum Zitat Cooper D, Moisan J, Gaudet M, Abdous B, J Gregoire (2005) Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can J Psychiatry 50:901–908CrossRefPubMed Cooper D, Moisan J, Gaudet M, Abdous B, J Gregoire (2005) Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can J Psychiatry 50:901–908CrossRefPubMed
3.
Zurück zum Zitat Nishikawa T, Hayashi T, Koga I, Uchida Y. (2007) Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study. Psychiatry: Interpers Biol Process 70:68CrossRef Nishikawa T, Hayashi T, Koga I, Uchida Y. (2007) Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study. Psychiatry: Interpers Biol Process 70:68CrossRef
4.
Zurück zum Zitat Harrow MH, Jobe TH, Faull RN (2012) Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. PsycholMed 42:2145–2155 Harrow MH, Jobe TH, Faull RN (2012) Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. PsycholMed 42:2145–2155
5.
Zurück zum Zitat Schooler NR, Goldberg SC, Boothe H, Cole JO (1967) One year after discharge: community adjustment of schizophrenic patients. Am J Psychiatry 123:986CrossRefPubMed Schooler NR, Goldberg SC, Boothe H, Cole JO (1967) One year after discharge: community adjustment of schizophrenic patients. Am J Psychiatry 123:986CrossRefPubMed
6.
Zurück zum Zitat Chouinard G, Chouinard V (2008) Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77:69CrossRefPubMed Chouinard G, Chouinard V (2008) Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77:69CrossRefPubMed
7.
Zurück zum Zitat Baldessarini RJ, Viguera AC (1995) Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52:189CrossRefPubMed Baldessarini RJ, Viguera AC (1995) Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52:189CrossRefPubMed
8.
Zurück zum Zitat Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/ discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70:913CrossRefPubMed Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/ discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70:913CrossRefPubMed
9.
Zurück zum Zitat Landolt K, Rössler W, Ajdacic-Gross V, Derks EM, Libiger J, Kahn RS et al (2016) Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). Schizophrenia Res 172:145–151CrossRef Landolt K, Rössler W, Ajdacic-Gross V, Derks EM, Libiger J, Kahn RS et al (2016) Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). Schizophrenia Res 172:145–151CrossRef
10.
Zurück zum Zitat Steiner W, Laporta M, Chouinard G (1990) Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatr Scand 81:437–440CrossRefPubMed Steiner W, Laporta M, Chouinard G (1990) Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatr Scand 81:437–440CrossRefPubMed
11.
Zurück zum Zitat Chouinard G (1991) Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment, Schizophr Res 5:21–33CrossRefPubMed Chouinard G (1991) Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment, Schizophr Res 5:21–33CrossRefPubMed
12.
Zurück zum Zitat Moncrieff J (2013) The bitterest pills: the troubling story of antipsychotic drugs. Palgrave Macmillan, LondonCrossRef Moncrieff J (2013) The bitterest pills: the troubling story of antipsychotic drugs. Palgrave Macmillan, LondonCrossRef
13.
Zurück zum Zitat Moncrieff J, Cohen D, Porter S (2013) The psychoactive effects of psychiatric medication: the elephant in the room. J Psychoact Drugs 45:409–415CrossRef Moncrieff J, Cohen D, Porter S (2013) The psychoactive effects of psychiatric medication: the elephant in the room. J Psychoact Drugs 45:409–415CrossRef
14.
Zurück zum Zitat Byrne R, Davies L, A Morrison (2010) Priorities and preferences for the outcomes of treatment of psychosis: a service user perspective. Psychosis 2:210–217CrossRef Byrne R, Davies L, A Morrison (2010) Priorities and preferences for the outcomes of treatment of psychosis: a service user perspective. Psychosis 2:210–217CrossRef
15.
Zurück zum Zitat McGorry P, Alvarez-Jimenez M, Killackey E (2013) Antipsychotic medication during the critical period following remission from first- episode psychosis: less is more. JAMA Psychiatry 70:898CrossRefPubMed McGorry P, Alvarez-Jimenez M, Killackey E (2013) Antipsychotic medication during the critical period following remission from first- episode psychosis: less is more. JAMA Psychiatry 70:898CrossRefPubMed
16.
Zurück zum Zitat Breggin PR (2013) Psychiatric Drug Withdrawal: a guide for prescribers, therapists, patients and their families. Springer Publishing Company, New York Breggin PR (2013) Psychiatric Drug Withdrawal: a guide for prescribers, therapists, patients and their families. Springer Publishing Company, New York
17.
Zurück zum Zitat Hall W (2012) The harm reduction guide to coming off psychiatric drugs, 2nd edn., The Icarus Project and Freedom Centre, USA Hall W (2012) The harm reduction guide to coming off psychiatric drugs, 2nd edn., The Icarus Project and Freedom Centre, USA
19.
Zurück zum Zitat Geyt GL, Awenat Y, Tai S, Haddock G (2016) Personal accounts of discontinuing neuroleptic medication for psychosis. Qual Health Res 26:1–16 Geyt GL, Awenat Y, Tai S, Haddock G (2016) Personal accounts of discontinuing neuroleptic medication for psychosis. Qual Health Res 26:1–16
20.
Zurück zum Zitat Salomon C, Hamilton B (2013) “All roads lead to medication?” Qualitative responses from an australian first- person survey of antipsychotic discontinuation. Psychiatr Rehabil J 36:160–165CrossRefPubMed Salomon C, Hamilton B (2013) “All roads lead to medication?” Qualitative responses from an australian first- person survey of antipsychotic discontinuation. Psychiatr Rehabil J 36:160–165CrossRefPubMed
21.
Zurück zum Zitat Salomon C, Hamilton B, Elsom S (2014) Experiencing antipsychotic discontinuation: results from a survey of Australian consumers. J Psychiatr Ment Health Nurs 21:917CrossRefPubMed Salomon C, Hamilton B, Elsom S (2014) Experiencing antipsychotic discontinuation: results from a survey of Australian consumers. J Psychiatr Ment Health Nurs 21:917CrossRefPubMed
22.
Zurück zum Zitat Jung E, Wiesjahn M, Wendt H, Bock T, Rief W, Lincoln TM (2016) Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. Psychol Med 46:2179–2188CrossRefPubMed Jung E, Wiesjahn M, Wendt H, Bock T, Rief W, Lincoln TM (2016) Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. Psychol Med 46:2179–2188CrossRefPubMed
23.
Zurück zum Zitat Larsen-Barr MT (2016) Experiencing antipsychotic medication: from first prescriptions to attempted discontinuation. University of Auckland doctoral thesis, New Zealand Larsen-Barr MT (2016) Experiencing antipsychotic medication: from first prescriptions to attempted discontinuation. University of Auckland doctoral thesis, New Zealand
24.
Zurück zum Zitat Read J, Cartwright C, Gibson K (2014) Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res 216:67–73CrossRefPubMed Read J, Cartwright C, Gibson K (2014) Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res 216:67–73CrossRefPubMed
25.
Zurück zum Zitat Zipursky RB, Menezes NM, Streiner DL (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152:408–414CrossRefPubMed Zipursky RB, Menezes NM, Streiner DL (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152:408–414CrossRefPubMed
26.
Zurück zum Zitat Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients: Review of the literature. Arch Gen Psychiatry 52:173–188CrossRefPubMed Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients: Review of the literature. Arch Gen Psychiatry 52:173–188CrossRefPubMed
27.
Zurück zum Zitat Davidson L (2011) Recovery from psychosis: What’s love got to do with it? Psychosis–Psychol Soc Integr Approaches 3:105–114 Davidson L (2011) Recovery from psychosis: What’s love got to do with it? Psychosis–Psychol Soc Integr Approaches 3:105–114
28.
Zurück zum Zitat Roe D, Goldblatt H, Baloush-Klienman V, Swarbrick M, Davidson L (2009) Why and how people decide to stop taking prescribed psychiatric medication: exploring the subjective process of choice. Psychiatr Rehabil J 33:38–46CrossRefPubMed Roe D, Goldblatt H, Baloush-Klienman V, Swarbrick M, Davidson L (2009) Why and how people decide to stop taking prescribed psychiatric medication: exploring the subjective process of choice. Psychiatr Rehabil J 33:38–46CrossRefPubMed
29.
Zurück zum Zitat Gibson S, Brand S, Burt S, Boden Z, O Benson (2013) Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. BMC Psychiatry 13:153CrossRefPubMedPubMedCentral Gibson S, Brand S, Burt S, Boden Z, O Benson (2013) Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. BMC Psychiatry 13:153CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Morrison AP, Hutton P, Shiers D, Turkington D (2012) Antipsychotics: is it time to introduce patient choice? Br J Psychiatry 201:83–84CrossRefPubMed Morrison AP, Hutton P, Shiers D, Turkington D (2012) Antipsychotics: is it time to introduce patient choice? Br J Psychiatry 201:83–84CrossRefPubMed
31.
Zurück zum Zitat Bentall RP, Morrison AP (2002) More harm than good: the case against using anti-psychotic drugs to prevent severe mental illness. J Mental Health 11:351–356CrossRef Bentall RP, Morrison AP (2002) More harm than good: the case against using anti-psychotic drugs to prevent severe mental illness. J Mental Health 11:351–356CrossRef
32.
Zurück zum Zitat del Barrio LR, Cyr C, Benisty L, Richard P (2013) Autonomous Medication Management (GAM): new perspectives on well-being, quality of life and psychiatric medication/Gestao Autonoma da Medicacao (GAM): novas perspectivas sobre bem-estar, qualidade de vida e medicacao psiquiatrica.(Author abstract), Ciencia & Saude Coletiva. 18 del Barrio LR, Cyr C, Benisty L, Richard P (2013) Autonomous Medication Management (GAM): new perspectives on well-being, quality of life and psychiatric medication/Gestao Autonoma da Medicacao (GAM): novas perspectivas sobre bem-estar, qualidade de vida e medicacao psiquiatrica.(Author abstract), Ciencia & Saude Coletiva. 18
33.
Zurück zum Zitat The Health and Disability Commissioner (1996) The code of health and disability services consumers’ rights, Wellington The Health and Disability Commissioner (1996) The code of health and disability services consumers’ rights, Wellington
34.
Zurück zum Zitat Irwin E, Mitchell L, Durkin L, Douieb B (1972) The need for a mental patients union (The Fish Pamphlet). Self-published, London, England Irwin E, Mitchell L, Durkin L, Douieb B (1972) The need for a mental patients union (The Fish Pamphlet). Self-published, London, England
36.
Zurück zum Zitat Campbell P, Roberts A (2009) Survivors’ history. Life Day 13:33–36CrossRef Campbell P, Roberts A (2009) Survivors’ history. Life Day 13:33–36CrossRef
37.
Zurück zum Zitat Gawith L, Abrams P (2006) Long journey to recovery for Kiwi consumers: recent developments in mental health policy and practice in New Zealand, Australian Psychologist, vol 41, pp 140–148 Gawith L, Abrams P (2006) Long journey to recovery for Kiwi consumers: recent developments in mental health policy and practice in New Zealand, Australian Psychologist, vol 41, pp 140–148
38.
Metadaten
Titel
Attempting to stop antipsychotic medication: success, supports, and efforts to cope
verfasst von
Miriam Larsen-Barr
Fred Seymour
John Read
Kerry Gibson
Publikationsdatum
23.04.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Social Psychiatry and Psychiatric Epidemiology / Ausgabe 7/2018
Print ISSN: 0933-7954
Elektronische ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-018-1518-x

Weitere Artikel der Ausgabe 7/2018

Social Psychiatry and Psychiatric Epidemiology 7/2018 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.